share_log

Watching MEI Pharma; Hearing Brookline Capital Reiterates Buy Rating, $80 Price Target

Benzinga ·  May 23, 2023 11:47
Watching MEI Pharma; Hearing Brookline Capital Reiterates Buy Rating, $80 Price Target
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment